TOPLINE:

Continuing metformin throughout the first trimester in women with polycystic ovary syndrome (PCOS) showed the potential to reduce miscarriage risk (odds ratio [OR], 0.64) and increase clinical pregnancy rates (OR, 1.57) compared with placebo. A meta-analysis of 12 randomized controlled trials involving 1708 women suggested that stopping metformin at pregnancy confirmation might be less beneficial than continuation through the first trimester.

METHODOLOGY:

Researchers conducted a systematic review and meta-analysis of randomized controlled trials evaluating metformin started preconception and continued at least until positive pregnancy test compared with placebo or no treatment in women with PCOS.

The analysis included 12 trustworthy studies with 1708 participants, with trials

See Full Page